NR3C2 and hydrops fetalis: All patients were on optimized medical therapy: ACEI/ARBs and ARNI were used in 19% and 81%, respectively; beta-blockers in 100%; mineralocorticoid receptor antagonists in 93%; and SGLT-2 inhibitors in 63%, and no major changes in HF medication were introduced during the 6-month follow-up (Table S1).